Podcasts about ampa

La comunidad educativa del colegio público El Pedregal de Castro Urdiales acude al Parlamento de Cantabria para escuchar las explicaciones del consejero de Educación, Sergio Silva, y conocer los verdaderos motivos del cierre del centro. Los representantes del AMPA consideran que es absurdo que el Gobierno regional se interpele a sí mismo.

Se puede votar hasta el 4 de marzo a través de la plataforma de la Secretaría Digital de la Conselleria de Educación

Od posledního dílu pořadu Na Východ! uplynul jen týden, ale jeho dramatické dění by vydalo hned na několik samostatných dílů. Americký prezident Donald Trump šokuje Evropu i prezidenta Volodymyra Zelenského výroky, které zpochybňují začátek ruské agrese vůči Ukrajině, legitimitu ukrajinské hlavy státu a ochotu USA bránit své spojence. Kyjev i Evropa čelí nepříjemnému výhledu, že je Spojené státy nechají v dosavadní obraně vůči Rusku na holičkách.

ENTREVISTA A INMA CAÑIZARES, PRESIDENTA DEL AMPA DEL CEE ANTONIO SEQUEROS DE ORIHUELA.10 DE FEBRERO DE 2025.TEMPORADA VII. Entrevista en los micrófonos de NO ME CAMBIES LA VIDA a Inma Cañizares, presidenta del CEE Antonio Sequeros de Orihuela. Te animamos a escuchar esta magnífica entrevista.

V žebříčku světově nejbohatších lidí nemá Česko mezi postkomunistickými zeměmi ve střední Evropě obdoby. „Musím každý rok v New Yorku dokládat, že máme opravdu tolik miliardářů. Oni to nechápou,“ říká Petr Šimůnek, který před čtrnácti lety do Česka přivedl legendární americký časopis Forbes.Jako u každé správné byznysové story, i úspěch Petra Šimůnka s časopisem Forbes začal pádem dolů. V roce 2011 nejprve coby úspěšný novinář a mediální manažer dostal vyhazov z pozice šéfredaktora Hospodářských novin. Jako pozici útěchy tehdy získal od vydavatelství Economia za úkol shánět mezinárodní projekty. Přišel s nápadem koupit licenci pro vydávání časopisu Forbes, Economia to ale vyhodnotila jako projekt bez šance na výdělek, odmítla a Petr Šimůnek odešel.Dva týdny poté dostal nabídku od slovenského nakladatelství MediaRey, SE vést českou mutaci časopisu Forbes. A přijal okamžitě.„Musím upřímně říct, že jsem nebyl první volba, chtěli někoho jiného, ale já jsem byl jediný, kdo byl volný. Člověk musí mít zkrátka taky štěstí,“ vypráví v nejnovějším díle podcastu Mediální cirkus Petr Šimůnek. Kromě nástupu na pozici šéfredaktora tehdy získal i desetiprocentní podíl ve slovenské firmě, která už Forbes vydávala na Slovensku a vlastnila práva pro českou mutaci.„Nebylo tak těžké to rozjet. Jednak moji společníci rok předtím rozjeli Forbes na Slovensku, takže měli rok náskok a zkušenost, kterou mi mohli dát. To byla velká výhoda na startu. Navíc to bylo v roce 2011 po velké celosvětové krizi, která se na začátku nejvíc dotkla právě médií. Forbes nevyjímaje. A jeden z důsledků byl, že se rozvolnila licenční pravidla a už nebyla tak přísná,“ popisuje Šimůnek začátky Forbesu v Česku.Časopis Forbes se v Česku stejně jako jinde po světě etabloval jako časopis, který píše o úspěchu a úspěšných, bohatých a luxusu.Forbes není objektivní médium„Je to určitě vždycky story o podnikání, o tom, jak někdo z ničeho udělal něco, to je americký sen. To myslím, že je univerzální věc, která platí na celém světě. Že lidi, které to zajímá, tak chtějí číst, jak se to stane, že se jako člověk rozhodneš, že nebudeš spoléhat na to, že ti přijde výplata od tvého zaměstnavatele, ale sebereš se a jdeš dělat něco sama pro sebe nebo sama za sebe. To je strašný risk a vlastně dodneška mě to fascinuje a fascinovat bude, že takových lidí je strašně moc kolem nás a že v Česku jsou lidé neskutečně podnikaví,“ popisuje Šimůnek.Smysl vidí i v psaní nejen o těch velkých: „My jsme psali o pekařích, malých pekárnách, cukrárně, o tom, že si někdo otevřel nějaký malý byznys, a to v Americe vůbec není. To je  specialita, kterou jsme tam přidali my. Ale přišlo nám, že lidi, kteří chtějí podnikat, se daleko lépe a jednodušeji identifikují s někým, kdo má nějakou malou věc na startu, než rovnou s nějakým miliardářem.“Luxus, o kterém Forbes píše, si Petr Šimůnek sám rád užívá a chce, aby k němu aspoň trochu nahlédli i lidé z jeho redakce.„V jakémkoliv médiu bych pracoval, tak chci, aby redaktoři věděli, o čem píší, aby tedy žili Forbes život. Mimochodem, je to docela návyková věc a není to tak těžké. Když se dávalo u nás zápisné, když někdo přišel nový, tak jsem vyžadoval, že to musí být šampaňské. Pravé šampaňské, ne prosecco nebo nějaká takováhle hrůza. Šampaňské, protože, sakra, my jsme Forbes, tam se nic jiného nepije,“ vypráví napůl vážně a napůl s úsměvem.Letos v lednu pro Petra Šimůnka ale jedna etapa Forbes života skončila. Ve vedení časopisu ho vystřídal Zdravko Krstanov. Zůstává ale ve vydavatelství MediaRey, SE, kde má majetkový podíl. A na starosti dostal, stejně jako kdysi v Economii, hledání nových příležitostí.Jak úspěšný je český Forbes v rámci světových mutací? A jak se posunula česká ekonomická novinařina?--Mediální cirkus. Podcast Marie Bastlové o dění na mediální scéně. Zajímá ji pohled do redakcí, za kulisy novinářské práce – s předními novináři i mediálními hráči.Sledujte na Seznam Zprávách, poslouchejte na Podcasty.cz a ve všech podcastových aplikacích.Archiv všech dílů najdete tady. Své postřehy, připomínky nebo tipy nám pište prostřednictvím sociálních sítí pod hashtagem #medialnicirkus nebo na e-mail: audio@sz.cz.

Neste episódio inspirador do podcast "Brasil que Produz", José Carlos Dolphine, produtor rural de Mato Grosso, compartilha sua trajetória de sucesso no agronegócio. Desde os primeiros anos no Paraná até a expansão em Campo Verde, ele detalha a evolução de sua fazenda, incluindo a diversificação de culturas (soja, milho, algodão), a importância das cooperativas e associações (Cooperfibra e AMPA) e a adoção de tecnologias para otimizar a produção. A conversa destaca a gestão eficiente, a sucessão familiar, os desafios impostos pela dinâmica do mercado e regulamentações e a construção de um legado baseado em sustentabilidade e responsabilidade social. Dolphine enfatiza a importância de valorizar os funcionários e a comunidade, demonstrando que o sucesso no agro vai além do lucro financeiro.

Neste episódio inspirador do podcast "Brasil que Produz", José Carlos Dolphine, produtor rural de Mato Grosso, compartilha sua trajetória de sucesso no agronegócio. Desde os primeiros anos no Paraná até a expansão em Campo Verde, ele detalha a evolução de sua fazenda, incluindo a diversificação de culturas (soja, milho, algodão), a importância das cooperativas e associações (Cooperfibra e AMPA) e a adoção de tecnologias para otimizar a produção. A conversa destaca a gestão eficiente, a sucessão familiar, os desafios impostos pela dinâmica do mercado e regulamentações e a construção de um legado baseado em sustentabilidade e responsabilidade social. Dolphine enfatiza a importância de valorizar os funcionários e a comunidade, demonstrando que o sucesso no agro vai além do lucro financeiro.

Do extremo oeste de Santa Catarina para o médio-norte de Mato Grosso. O caminho percorrido pelo nosso convidado foi o mesmo de muitas pessoas que trocaram o sul pelo centro-oeste em busca de novas oportunidades. Para o catarinense de Anchieta, a mudança no início dos anos 80 também significou a entrada definitiva dele no agro, de onde nunca mais saiu. A fazenda, localizada em Sorriso, é motivo de orgulho: com diferentes cultivos e pecuária de ponta, virou exemplo de sucesso em diversificação. Fora da propriedade, o “seo" Nelson Piccoli também é referência. Tem longa trajetória no cooperativismo e no associativismo classista junto a sindicatos e entidades ligadas ao setor produtivo. É o atual presidente da Organização das Cooperativas Brasileiras em Mato Grosso e, nesta semana, foi eleito para também conduzir o Fórum Agro MT, que é formado pela Acrimat, Acrismat, Ampa, Aprosmat, Famato e pela própria OCB-MT. No bate-papo, fala sobre as perspectivas e os desafios do cooperativismo e do agro para os próximos anos. Reforça a importância do avanço da industrialização do estado, destacando que além de agregar valor à matéria-prima que sai dos nossos campos, esta verticalização gera renda, empregos, mudanças de vida e transforma regiões.See omnystudio.com/listener for privacy information.

La directora destaca el apoyo de las familias y el constante crecimiento del colegio: “Un grupo ha formado el AMPA, y ellos han creado el coro, con el que han realizado ocho conciertos en nuestro entorno”.

Hoy ha comenzado en el IES Menárguez Costa de Los Alcázares un proyecto cofinanciado por la Consejería de Educación y el AMPA, que ofrece un espacio de escucha para que los alumnos aborden temas como relaciones, conflictos, acoso, familia, estudios o salud mental. Estará activo hasta marzo y hemos conversado con la profesora Yolanda Ramírez y el psicólogo especialista Gabriel González.

Nos trasladamos hasta Catalunya, para contactar con Olga Perea, Neurologopeda, madre de un adolescente con discapacidad. Olga, es de esas mujeres que a base de mucho esfuerzo logran su objetivo, en este caso estudiar y tener que cuidar de su hijo con dificultades de aprendizaje. Finalizamos el programa de hoy, hablando de lo mal que está la atención a la discapacidad en las residencias en Gran Canarias, para ello tenemos como interlocutora a la presidenta del AMPA del Centro Reina Sofía, Elena García, hermana de un usuario que recibe atención en dicho centro.

Matjaža na ultrah skoraj nič ne more presenetiti, ker ima zanimivo tekaško filozofijo - in teflonski želodec! Debatirala sva o tem, kako ga je trail osvojil in zasvojil, kako je okužil še ženo, zakaj se tako rad vrača na UTMB, kaj so zanj ključne sestavine uspešnega ultraša (namig: ni trening!) in njegovih hudo zanimivih prigodah od Diagonale norcev do Omana, od Baške grape do Istre. Hecala sva se tudi o mrzli vodi, družinskih duelih, socialnih omrežjih, telefonskih klicih sredi noči in bruhanju. Pa še mnogo več - tole je ultra poslastica!

La presidenta del AMPA, Itziar Casanueva y Borja Cervera, portavoz de los profesores

Desde la Plataforma en Defensa del Parque de la Alameda de Jaén informan que, “a raíz de las obras del Centro de Salud, hay grietas y supone un grave peligro”. Violeta García, del AMPA del Colegio Jesús y María, y Javier Ramírez, de Ecologistas en Acción, han acudido a los estudios de Radio Jaén Cadena SER para ser entrevistados en el espacio ‘Hoy por Hoy'.

Až si budeme přát hodně zdraví v roce 2025, připijeme si asi nejčastěji šumivým vínem. Kdyby to náhodou bylo originální šampaňské, tak si připravte kousek papíru. Hodil se i Petru Hladíkovi.

La secretaria del AMPA del IES 25 de abril de Alfafar, Susana Mozos, denuncia la situación de abandono que vive su centro, donde no han podido retomar las clases porque la Consellería de Educación del gobierno valenciano no les entrega un certificado de seguridad estructural.

La secretaria del AMPA del IES 25 de abril de Alfafar, Susana Mozos, denuncia la situación de abandono que vive su centro, donde no han podido retomar las clases porque la Consellería de Educación del gobierno valenciano no les entrega un certificado de seguridad estructural.

La secretaria del AMPA del IES de abril de Alfafar, Susana Mozos, denuncia la situación de abandono que vive su centro, donde no han podido retomar las clases porque la Consellería de Educación del gobierno valenciano no les entrega un certificado de seguridad estructural.

Se trata de un publicación sin carácter comercial que en sus 120 páginas muestra productos que han pasado controles exhaustivos, así como un estudio sobre los hábitos infantiles a la hora de jugar

"He who is faithful in a very little thing is also faithful in much; and he who is dishonest in a very little thing is also dishonest in much.” - Luke‬ ‭16‬:‭10‬ ‭AMPA visual learner? Watch the stream back now! Hosted on Acast. See acast.com/privacy for more information.

Investigan el hallazgo de gusanos en el arroz servido en el comedor de un colegio público de Málaga

El consistorio asegura que ha transmitido al AMPA del centro que la planta superior de las nuevas instalaciones, junto con el ascensor y la escalera exterior, entrarán en funcionamiento en los próximos días

Se concentrarán este miércoles a las 17.00 h en la plaza del Hidalgo Caballero

La Agrupación Local de AMPA de Elda muestra su apoyo a las familias del CEIP Padre Manjón

La actriz se sube a las tablas del Teatro Reina Victoria para protagonizar Inmaduros, una comedia sobre la crisis de los 50 y las nuevas formas de relacionarnos.Conocida por sus papeles en las series 'Amar es para siempre', 'Señoras del (h)AMPA' o '30 monedas'... y en películas como 'El maestro de esgrima', '¿Por qué lo llaman amor cuando quieren decir sexo?' o 'Cha-cha-chá'... Conocemos más sobre esta actriz sevillana que ha destacado por su capacidad para adaptarse a diferentes formatos de cultura y entretenimiento.

La actriz se sube a las tablas del Teatro Reina Victoria para protagonizar Inmaduros, una comedia sobre la crisis de los 50 y las nuevas formas de relacionarnos.Conocida por sus papeles en las series 'Amar es para siempre', 'Señoras del (h)AMPA' o '30 monedas'... y en películas como 'El maestro de esgrima', '¿Por qué lo llaman amor cuando quieren decir sexo?' o 'Cha-cha-chá'... Conocemos más sobre esta actriz sevillana que ha destacado por su capacidad para adaptarse a diferentes formatos de cultura y entretenimiento.

In dieser Epiode sprechen Prof. Dr. Andrew Plested und Bernd Rupp über Ionenkanäle, ihre Rolle im Gehirn und wie der AMPA-Rezeptor elektrische Signale steuert.

Elena Jiménez, AMPA Colegio ‘Antonio Machado' de Peal de Becerro, asegura que “era un colegio referente, con tres edificios, y nos hemos quedado con uno”. Declaraciones de Jiménez en el programa Hoy por Hoy de Radio Jaén Cadena SER. Los padres y madres de alumnos han vuelto hoy, un miércoles más, a las protestas ante la falta de explicaciones por parte de la Junta de Andalucía sobre las obras que se prometieron en el centro hace cuatro años y de las que nada se sabe.

CCOO denuncia en Málaga la deficiente atención al alumnado con necesidades educativas

El jueves 3 de octubre ofrecerá en Elda dos acciones formativas de la mano de la Agrupación Local de AMPA

El lema es "antes nos crecen árboles que nos abren el comedor"

Nosso Algodão se profissionalizou, é todo Certificado, e isso está ajudando a conquistar novos mercados. Sem mimimi nem choradeira.

Charlamos sobre los bulos con nuestro experto en fakes Marc Amorós. Hablamos con Lucía Riera y Victoria García sobre la justicia francesa que retira su estatus de medio de comunicación a France Soir. Conversamos con Alba Abdel-Fatah es la secretaria del AMPA del Colegio Público Gómez Moreno. Charlamos con abogada y experta en legalidad del homeschooling en EspañaVioleta Cuesta.

La propuesta del AMPA del Colegio Público Gómez Moreno superó en todos los criterios a la otra empresa, que se impone en el apartado económico

Short-term decision making has dominated economic, environmental and social governance in recent years. Economic decisions in particular have appeared to be made without proper long-term foresight. In this episode of Fisher German talks, we highlight the importance of thinking long-term when you're planning a sustainable business. Here's how to plan effectively for the future. Andrew Bridge, Managing Partner at Fisher German, is joined by Sarah Walker-Smith and John O'Brien. Sarah is CEO of Ampa, Chief Executive of Shakespeare Martineau, Chair at the Eden Project Morecambe, Past Governor at NTU and advisory board member at Anthropy. John is the Founder and Chairman of Anthropy, and the Former EMEA Managing Partner of Omnicom's 100 Agency Group and a veteran of the British Army. He has over 40 years of multi-sector leadership experience and has run organisations in over 20 countries, and is a best selling business author with a WH Smith no3 & Forbes Top 125 Leader's Read. Together they discuss the importance of a purpose-driven business model (one that goes beyond short-term profits), connecting personal purpose with business (Sarah discusses the ways in which she uses workshops and initiatives to inspire innovation), and the evolution of corporate responsibility to ESG governance (the focus should be on embedding ethical practices into a companies DNA, John explains).

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Eoin P. Flanagan, MBBCh, FAAN who served as the guest editor of the Continuum® August 2024 Autoimmune Neurology issue. They provide a preview of the issue, which publishes on August 1, 2024. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Flanagan is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Additional Resources Continuum website: ContinuumJournal.com Subscribe to Continuum: shop.lww.com/Continuum More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @EoinFlanagan14 Transcript Full episode transcript available here   Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based  neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, a companion podcast to the journal. Continuum Audio features conversations with the guest editors and authors of Continuum, who are the leading experts in their fields. Subscribers to the Continuum journal have access to exclusive audio content not featured on the podcast. If you're not already a subscriber, we encourage you to become one. For more information, please visit the link in the show notes.    Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Eoin Flanagan, who recently served as Continuum's guest editor for our latest issue on autoimmune neurology. Dr Flanagan is a neurologist at Mayo Clinic in Rochester, Minnesota, where he's a professor of neurology. Eoin, why don't you introduce yourself to our listeners?   Dr Flanagan: Yeah, it's a great pleasure to be here today. I'm a neurologist. I'm originally from Ireland – I did my medical school training over there, and then came over to the Mayo Clinic to train in neurology and in neuroimmunology. And delighted to be able to edit this exciting issue of autoimmune neurology of Continuum. I think, um, it's a really fascinating area that's moving very quickly, and I'm hoping that we can educate listeners to be able to feel comfortable when they come to see these patients and to realize how much of a growing specialty it is and how we're getting treatments, and we can really help these patients.     Dr Jones: Yeah, it's a pretty exciting area. And, so, not only are you the Guest Editor for our latest issue of Continuum, this is the first-ever Continuum issue dedicated to autoimmune neurology, so I want to thank you for taking it on. This is something that our readers have been asking for for many years. I hope the topic wasn't too daunting.   Dr Flanagan: No, absolutely, it's a pleasure to be able to do it, and it's just great when you read all the articles to kind of feel where the field is going and how much of  a benefit we can now make for our patients. So, that's been a real joy to do.   Dr Jones: Well, congratulations, and it's a magnificent issue. You have a lot to be proud of putting this group of authors together. So, for a few of our issues now, we've had the opportunity on the Continuum Audio podcast to interview the Guest Editor, which is really fun for me. I have to confess it's really a joy to talk to someone who is up to the minute not only in their narrow area of expertise at the article level, but, really, across the entire breadth of the subspecialty. And so, you've had an opportunity to delve into all relevant topics in autoimmune neurology. When you look at the issue as a whole, or the field as a whole, what do you think the biggest debate or controversy in the world of autoimmune neurology is right now?     Dr Flanagan: Yeah, I think there's some changes happening. You know, initially, people used to recognize a disease called Hashimoto's encephalitis, where patients would have a presentation of encephalitis in the setting of thyroid antibodies. And what we're now realizing is that many of these patients actually have antibodies to neural-specific targets, because we know that the antibodies that target the thyroid don't really impact the brain. And what we're now realizing is that there's many antibodies out there that bind to different receptors in the brain (the NMDA receptor, for example, AMPA receptor), so we're really trying to refine the field towards these different antibody-associated disorders - and each different disorder may behave very differently. A patient with NMDA receptor encephalitis, for example, may be in the ICU, in hospital, may take them six, nine months to recover. On the other hand, a patient with LGI1-antibody encephalitis may get five days of steroids and be almost back to normal within a few weeks. So, it's a really broad spectrum. And, I think, what we're now learning is that each antibody has a role in helping define the disease, guide your treatment, guide your search for cancer - but, also, they behave differently - so these neural-specific antibodies are really important, while the older antibodies (like the thyroid antibodies) may just be a bystander and something that's happening in the background in a patient who's more prone to autoimmune disease.   Dr Jones: Very helpful, and I think that resonates with our listeners who have taken care of patients with autoimmune neurologic disorders, and it really is, I think, a great prototype in our specialty, maybe (for lack of a better word) of how observations start at the bedside, and then discoveries are made at the bench, and those benefits are brought back to patients. You know, there's been a recognition of autoimmunity in neurology for a long time, right - responsiveness to immunosuppression, even before the biomarkers were discovered - tell us a little story about how that works for our listeners.    Dr Flanagan: Yeah, so, I think one of the first steps is defining a clinical syndrome. So what you'll find is that some of these syndromes (for example, neuromyelitis optica spectrum disorder, where they have longitudinally extensive lesions within a spinal cord) provoked people to be interested that these looked different to MS, and then that went to the lab, and the aquaporin-4 antibodies were discovered - or, more recently, MOG antibodies were discovered. The aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder is a good prototype, because that went to the laboratory. Initially, they saw complement deposition on the pathology of these patients, they saw antibody deposition - the antibody was then discovered to aquaporin-4. And then, many labs around the world went to their own labs and they tried to delve in to determine what the pathogenesis was, and they found that complement was important in cell killing, that interleukin-6 elevation was important, and that complement appeared to be important. So, then, what they did was they tried to find treatments that would target those pathways. So, and now, we have treatments that are successful for this disease that can target complement, target interleukin-6, and target B cells (be it CD19 or CD20). So, we now have many different treatments, and this disease used to be very severe (so, had a 33% mortality at five years), and now these patients can live a long life with these treatments. So, I think that gives you an example of how you can follow the immunology of the disease and use targeted treatments to help our patients, and I think we can use that as a good prototype for many of   the other antibodies, because every year we discover two to three new antibodies, and each disease is a bit different in its mechanism. So, there are now clinical trials in NMDA receptor encephalitis starting up. There's clinical trials in MOG antibody-associated disease. And I think we're going to see that as we move forward, that these treatment trials will come and we'll be able to help our patients better with proven treatments that we know work, rather than a history of we would just use five days of steroids and then we didn't know exactly what to do in the long term - and we could manage some of the relapse as well, but we couldn't really take care of the disease in the background - so, I think the NMO is a good model for moving forward, and the pharmaceutical companies are supporting moving forward with different trials for the disease.   Dr Jones: So, a key message there is understanding the biology so we can be a little more targeted and less indiscriminate in the immunomodulation we're going to use. And we have parallels to that in the neuromuscular world, right, like using B-cell depletion for MuSK-associated neuromuscular junction disorders, as opposed to the trial-and-error approach, right? That's got to be a little more patient-centric and you get to a therapeutic response faster, right?   Dr Flanagan: I think so. Yeah, and I think, in the future, that might be something where, you know, a different patient, if they had elevated cytokines that pointed more to an IL-6 elevation, then maybe, in that patient, you would target IL-6, while the next patient with the same disease has more prominent complement activation, maybe you would target complement, or another patient has more prominent B-cell markers elevated, that you would target B cells. So, I think, we're really moving towards a more individualized treatment in some of these disorders. So, it's a very exciting time, but we've only really made that breakthrough in one of the antibodies, and we have probably sixty, seventy antibody-mediated disorders now. So, it's going to get complicated, but it's also going to be, really, an exciting time for our patients, and I think an exciting time for neurology trainees and people who see patients in practice that we can now make diagnoses and guide their treatment that, previously, you know, these patients were told they might have presumed infectious encephalitis or we didn't know the exact cause.   Dr Jones: So targeted not only to the diagnosis, but to the individual.   Dr Flanagan: Yeah.   Dr Jones: So, that's a level of complexity that I think is going to blow a lot of our minds, right? And it's exciting, but I think it also is a little daunting, right?   Dr Flanagan: Absolutely. Yeah. Yeah, it's going to be complicated, and these are rare diseases, so they're difficult to do clinical trials in. But I think we can be guided, and our experience tells us that if you follow the mechanisms, that you can find targeted treatments. Now, you can also find targeted treatments in MS - you know, it took us a longer time to find successful high-efficacy treatments, but now we're doing much better with many high-efficacy treatments available. But, I think in these autoantibody-mediated diseases, really looking at the mechanisms and trying to figure out that and then targeting the treatment in that direction makes the most sense and is the most likely to be successful.   Dr Jones: So, one of the purposes of Continuum is to educate our readers and our listeners, and because neurology is so broad, because it is evolving so quickly,   it's really hard to stay current. And so, again, that's part of the purpose of the journal. I think one of the challenging areas is autoimmune neurology, because it changes fast, and it's complicated, and the treatments are high stakes and complicated to administer - so, I think this is an important topic. I know from my own experience in clinical practice, one of the challenging scenarios is you see   a patient who may have an autoimmune neurological disorder, you obtain some serum or CSF markers of neurologic autoimmunity, right? And of the ten antibodies you check, one of them comes back, and it's a low titer-positive antibody. I know that's something that you get a lot of questions about. How do you approach that?     Dr Flanagan: Yeah, I think, you know, we're all neurologists, and, you know, it's immediately back to the history, the examination, and the investigations, and what do they support - so, are you really dealing with an antibody-mediated disorder? And I think, from a neuroimmunology laboratory standpoint, we're always trying to get better tests, remove those less-specific tests (so, move away from the thyroid peroxidase antibodies) and really hone in on the exact targets and their mechanisms. So, I suppose, when you find a low-positive result, it's really important to go back to that clinical. And, I think, you know, that is job security for neurologists, right? Because you really have to interpret these in context. And, I think when you're seeing autoimmune cases, you need to have a good, broad understanding of differential diagnosis, because there are many different disorders that can present in a similar way, and you don't want to get distracted by that low-positive antibody and then put a patient on long-term immunosuppression that has many different risks. So, there is a potential for misdiagnosis, and I think that's an emerging area that we're recognizing that we always have to put the antibodies into clinical context. And, you know, there are more and more studies coming out that will help guide you, and I think the issue in Continuum will help guide you in terms of your understanding of, you know, what does a positive antibody mean? And it'll give a little bit on the methodology of how the antibodies are tested and how that can help you – or, sometimes, be it the titer may be very high that can help you. So, different aspects of the antibody test results can also help guide you in the likelihood of that being kind of a true positive versus a false positive. But I think always back to the history, exam, and the investigations, too.   Dr Jones: You're being very gracious there, and I'm glad you bring it up that it's really not just about the laboratory performance of the test, right? It's about the pretest probability of the clinical syndrome if it doesn't clinically resemble an autoimmune neurological disorder. So, I'm not going to pretend to be an expert in Bayesian statistics, but I think we should recognize that if we obtain any test when there's a low likelihood of the syndrome or the diagnosis being present, we're more likely to have false positives than in other scenarios or other settings. So, I think that is a charge to the clinician, where if we are obtaining these tests, we do really need to think about the likelihood of there being a clinical autoimmune neurology syndrome, right?   Dr Flanagan: That's exactly right. You know, one of the teachings that I sometimes give to the trainees is that, you know, if you have a ninety-year-old patient with mild cognitive impairment who comes into the emergency department with some worsened altered mental status, you know, you want to check for a urinary tract infection, you want to check a chest x-ray - you don't want to test neural antibodies upfront. So, you always have to consider the setting and avoid overtesting, because like any test, they're not perfect, and you can run into trouble if you order it too frequently - so, that's another thing that we try to educate people. And then if you do order the test, we like to educate people on, you know, what the positive test results mean, and is there any potential for false positives like we talked about?   Dr Jones: And I think, keeping in mind - obviously, there are exceptions - but the subacute onset of multifocal neurological disorder is really suggestive of autoimmunity. It doesn't mean that it can't happen in other contexts. And it has been exciting not only on the diagnostic side, but on the therapeutic side. There are so many exciting new treatments. What do you think is on the horizon beyond what we've seen in the last few years with small- and large-molecule therapies for these disorders?     Dr Flanagan: Yeah, I think there's new things. You know, people are always looking at different approaches. So, for example, there's a lot of interest in tolerance, and is there a way you could tolerize yourself out of some of these autoimmune conditions? There's a lot of work on CAR-T treatments, looking particularly in the field of lupus and other systemic autoimmune diseases, and I suspect that they will also be applied to autoimmune neurologic conditions. And then the other thing to mention is that we're seeing the more frequent use of immune checkpoint inhibitors in patients with lots of different types of cancers, including neuroendocrine tumor. So I think, in the future, everybody's going to have to learn about autoimmune neurology, because we're going to be seeing these patients more often, because there's going to be more neurologic immune-related adverse effects related to those immune checkpoint inhibitor treatments – so, I think we're going to continue to see autoimmune neurologic disorders pop up. And, you know, the immune checkpoint inhibitors are almost real-world laboratory experiments, because you're ramping up the immune system, and you can trigger many different types of autoimmune conditions. We're actually learning a lot from these patients that can help us in the way we diagnose and the way we treat these patients in the future, but I will say that, sometimes, they can cause a challenge, because some of these patients have difficult-to-control cancer - you need to up their immune system, but then they get autoimmune complications. We try and dampen down the immune system, and then we need to kind of ramp it back up to treat the cancer. And we've had some challenges where managing such cases can be difficult with that balance of cancer-directed immunotherapy versus immune-related adverse events, and, sometimes, that can pose a challenge for autoimmune neurologists when we see these patients.   Dr Jones: So, those are challenges, and I imagine it's a challenging and often rewarding field. What is the most rewarding thing about caring for patients with autoimmune neurological disorders?     Dr Flanagan: I think it's a few things. You know, one is that it's a multidisciplinary area,   so many of these patients will have different subspecialties of neurology involved. So, we'll get to work with our colleagues, and we may work with our oncology colleagues, we work with our ophthalmologist, and we work with our physical medicine and rehab team – so, it's a real team approach to help the patient. So, that's one aspect that's very enjoyable, because everybody needs to work together. And then, you know, these are treatable conditions. So we can have patients who are in the intensive care unit - you know, quadriplegic, in a coma - and then we treat them, we see them back, and they can be back close to normal. So, particularly, with some of these antibodies that target the cell-surface receptors (like NMDA receptor encephalitis, MOG antibodies), these patients can really go from being really, really sick in the ICU to coming back to normal – so, that's very satisfying, and much of that is related to the improvements we have in treatments, and then we can manage them in the long term with some of these newer treatments that are coming along for these diseases. So, I think it's a very exciting area and exciting time for our patients with these disorders, and we're getting more and more clinical trials, so we're hoping that we'll have more and more treatments available into the future.   Dr Jones: I think that has to be part of why the interest in autoimmune neurology has grown so much. I know as an educator - I hear this a lot from trainees - you know, the level of interest in MS and autoimmune neurology has really only grown over time. It must be because of better understanding of the pathobiology of disease, better treatment options, and something that our listeners may not know. Not only is Dr Flanagan an expert in autoimmune neurology - he's very well trained, he did fellowship in MS and autoimmune neurology, and behavioral neurology, right?   Dr Flanagan: That's correct. Yeah. Yeah.   Dr Jones: And, you know, it's going to sound like I'm trying to flatter Eoin here, but I'm really not (this is going to lead to a question). Eoin is, you know, very well recognized for his work in autoimmune neurology and discovery in this area. Uh, he happens to be one of the best doctors I know. And Eoin, you've won the Teacher of the Year Award several times. So, for our listeners who are looking into their careers and trying to manage multiple areas of interest, how do you do it? You do so many different things so well.   Dr Flanagan: Well, you know, I'm lucky to have had the opportunity to work here at the Mayo Clinic and in the neuroimmunology lab. So, we have a lot of resources, and it's an exciting area, you know? We need to bring up the next generation of leaders, so we need to be enthusiastic about these conditions, and we really can do a lot for these patients. So I think when I cover on the hospital service - you work with the residents or work with the fellows and clinic - you know, these cases (when they come around) are really enjoyable to see you can get an answer, we can figure out what type of treatment to do, and we can really help these patients. So, I think that makes it a very exciting area and an easy area to teach residents and to convey some of the excitement that's happening in the field. So, it's just a great honor to be able to work with trainees to kind of let them know the field. And, you know, there's more and more fellowship opportunities in different centers in neuroimmunology, and I think more residents are becoming interested in the field of autoimmune neurology because of so much happening. But, in saying that, with these challenges, it's very hard to keep up with all these antibodies - I find it hard. There's 70 different antibodies - it's hard to know every single thing about every single one. So, we need to continue to educate, to try and simplify, to try and help our younger people be able to manage these patients, because no matter who it is in neurology, you're going to encounter these patients - if you cover the hospital, if you see regular patients in clinic, if you do consult service, you'll come across these patients - and we're going to see them more and more with immune checkpoint inhibitors and other treatments coming along. So, I think it's an exciting area, and it's an important area for everyone to be aware of. So, it's just a great pleasure to be able to be involved in the field and see such enthusiasm in junior people.   Dr Jones: So, in addition to doing all those things well, you're also very humble. So, that's a great answer, and I think it is important - even though these are collectively rare - the opportunity to treat these patients and have wonderful outcomes is great, and I think the ability to recognize and feel comfortable. And, hopefully, Continuum has a place in that. I think your issue, Dr Flanagan, is a stellar issue and, uh, will be a benchmark for a generation of neurologists and how to approach these disorders. So, I want to thank you for being our Guest Editor for that topic and joining us today for such a thorough and fascinating discussion on autoimmune neurology.   Dr Flanagan: Thanks so much. And thank you to the Continuum team for highlighting autoimmune neurology. It's an exciting field, and I think, really, there is a great group of authors that cover neuroimmunology comprehensively, and I think, hopefully, people will enjoy the edition.   Dr Jones: Again, we've been speaking with Dr Eoin Flanagan, Guest Editor for Continuum's most recent issue on autoimmune neurology. Please check it out. And thank you to our listeners for joining today.     Dr Monteith: This is doctor Teshamae Monteith, Associate Editor of Continuum Audio.   If you've enjoyed this episode, you'll love the journal, which is full of in-depth   and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.(00:32) Could you please give our listeners an overview of your role at Mayo Clinic? (01:22) What updates are happening in our laboratory to increase specificity when we receive a patient's serum and CSF for most of the CNS evaluations? (03:48) Why are these updates and additions important in the larger disease state?(06:16) Could you expound upon the relationship between the clinical practice and the lab? (08:32) What do these changes mean for patient care? (10:27) What about the inclusion of AMPA in the pediatric evaluation, and the inclusion of IgLON5 with autoimmune axonal? (12:58) How does your lab discern when it's time to add a biomarker? (15:44) What are you most excited about?

O especialista em Logística de transporte, Luiz Antônio Pagot, trabalha pela AMPA, para melhorar as possibilidades de exportação do nosso Algodão.

Rincón de la Victoria se convierte durante estos días en sede nacional de las ciencias con la celebración del XVI Encuentro de Ciencias Bezmiliana que recibirá la visita de más de 2.000 personas. El alcalde de Rincón de la Victoria, Francisco Salado, junto al delegado de Desarrollo Educativo y Formación Profesional de la Junta de Andalucía en Málaga, Miguel Briones, la concejala de Educación, Belén Gutiérrez, el director del IES Bezmiliana, Manuel Espinosa, el representante del Club Científico, Jesús Moreno, e inspector del centro, Juan José Casado, han participado en el acto de de inicio del Encuentro de Ciencias. El regidor ha asegurado que “este Ayuntamiento tiene que estar colaborando con el IES Bezmiliana por despertar en el alumnado el interés científico, de investigación, creativo e innovador. Hay mucho talento en los estudiantes de la provincia de Málaga, y necesitamos que se incorporen a la ciencia, para que tengamos más calidad de vida, que avancemos en apartados tan importantes como la ingeniería, las telecomunicaciones, medicina, y en general en todos los ámbitos”. Salado también ha tenido palabras de “agradecimiento, de orgullo y reconocimiento al instituto Bezmiliana por estos dieciséis años de encuentros científicos, que crecen en relevancia, participación de centros de la provincia, y que se hace internacional este año con la presencia de una delegación de una institución universitaria de Envigado (Colombia)”. Además, el alcalde ha destacado la colaboración de la comunidad educativa, AMPA, y la Junta de Andalucía porque sin su apoyo sería inviable estos encuentros, “donde existe mucho talento, y de donde saldrán futuros inventores en distintos ámbitos crear soluciones antes las necesidades y problemas de la sociedad”. Por su parte, Briones ha agradecido al IES Bezmiliana la celebración “de estos encuentros con la ciencia, y que representa una apuesta clarísima por la adquisición de competencias en materia científica y que tanto tiene que ver con el progreso y crecimiento económico”. El director del IES Bezmiliana ha destacado “la oportunidad que supone para la comunidad educativa disfrutar durante estos días con los experimentos y el mundo de las ciencias que va a marcar un referente en nuestros estudiantes”. Por su parte, el representante del Club Científico ha dicho que “hoy culmina el trabajo de todo un año por parte de los docentes, alumnado, padres y llevándolos a la calle para compartirlos con todo el municipio”. La concejala ha valorado “la repercusión internacional de este encuentro, de una dilatada trayectoria, en el que participan directamente unos 400 alumnos y 50 profesores procedentes de diversos centros educativos de la provincia”. El Club Científico Bezmiliana en colaboración con la Concejalía de Educación del Ayuntamiento de Rincón de la Victoria desarrolla durante estos días una amplia programación de actividades, que comenzó el pasado lunes 22 de abril en el propio IES Bezmiliana con charlas, conferencias, talleres, exposiciones, y se traslada hoy y mañana a la Plaza de la Constitución que acoge 22 carpas donde se muestran experimentos por parte del alumnado de los distintos centros participantes. La plaza de la Constitución acoge entre hoy y mañana la feria `La Ciencia en la calle” en formato abierto en horario de 09:00 a 14:00 horas. Esta XVI edición está contando con personalidades destacadas como Blanca Troughton, miembro destacado de la sociedad malagueña de Astronomía, y reconocida profesora, divulgadora y artista; Carlos Durán, profesor, divulgador y miembro de la asociación MECYT. También están presentes instituciones como la Real Sociedad Española de Química, sección territorial de Málaga, el Centro de Profesorado de Vélez-Málaga, la asociación Amirax, la Cátedra Hedy Lamarr de la Escuela Técnica Superior de Ingeniería de Telecomunicaciones (UMA), el Club Ajedrez Victoria, la Fundación Descubre, el AMPA Gran SOL y, toda la comunidad educativa del IES Bezmiliana. Toda la información sobre el XVI Encuentro de Ciencias Bezmiliana se puede consultar en www.clubcientificobezmiliana.org

In Part 2 of the Excitation and Inhibition phenomena, we discuss Metabolic "bank" account and demands of navigating the social world. We discuss if we have enough resources or if we will run a metabolic deficits (think burnout and avoidance, and social isolation). We cover NMDA and AMPA and different Autistic Phenotypes. In addition, we review Neuromodulators, which are vast in our biology and determine how and where to direct our attention and energy. Lastly, we discuss the medial Prefrontal Cortex and how it integrates the "self" with the outside world.Don't try to change an Autistic person because they are different than you or different than others. Don't let that offend your beliefs and capacity to apply critical thinking in life.https://www.nature.com/articles/s41398-023-02317-5https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723386/https://www.nature.com/articles/s41398-018-0155-1https://www.nature.com/articles/nature10360https://onlinelibrary.wiley.com/doi/full/10.1034/j.1601-183X.2003.00037.x?sid=nlm%3Apubmedhttps://www.nature.com/articles/s41380-022-01506-w(0:00) Introduction; Know Autism and Make Informed Decisions; Biological Aspects influencing Excitation / Inhibition Phenomena(4:30) Metabolic "Bank" Account and Resources; E/I creates criteria A and B; NMDA and AMPA, and more on the Striatum(10:02) Neuromodulators- Serotonin, Dopamine, Epinephrine and Norepinephrine, Acetylcholine; Active versus Passive Coping; Activating Systems and Cells and influencing Learning and Memory (Neuroplasticity); Nicotinic Receptors and Rapid-Excitation(15:20) medial Prefrontal Cortex (mPFC)- Metabolic demands and planning while considering Feelings, Integrating the Self and the Outside World; How E/I interacts; a brief explanation on Default Mode Network; Quieting the Body, or not; Information-Processing; Thalamocortical(20:19) Pursuits and Preference- Wanting and Having and being Autistic is fine, and others need to accept our phenotypes; sensory-input causes Faster Firing Rates in normal E/I- Image an imbalanced E/I(22:25) Wrap-up and understanding Autism, and Contact Info

En este episodio #134 contestamos preguntas de la banda de instagram, hablamos de la Santa patinada en Mazatlan, el evento de Hermosillo con Steve Caballero, skateboarding femenil, Ampa am kids en la perla... Eso y mucho mas en Efecto Ollie

„Výsledek slovenských prezidentských voleb byl pro mne celkem překvapením, a to velmi nepříjemným. Protože jsem věřil, že se většina voličů na Slovensku vzpamatuje. Protože stojíme na křižovatce, a buď se vrátíme do minulosti, nebo budeme pokračovat na cestě, na kterou jsme se vydali po roce 1989,“ říká bývalý politik, bývalý kandidát na slovenského prezidenta a herec Milan Kňažko.

„Výsledek slovenských prezidentských voleb byl pro mne celkem překvapením, a to velmi nepříjemným. Protože jsem věřil, že se většina voličů na Slovensku vzpamatuje. Protože stojíme na křižovatce, a buď se vrátíme do minulosti, nebo budeme pokračovat na cestě, na kterou jsme se vydali po roce 1989,“ říká bývalý politik, bývalý kandidát na slovenského prezidenta a herec Milan Kňažko.Všechny díly podcastu Osobnost Plus můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Best in Class Life Improvement, published by sapphire on April 4, 2024 on LessWrong. There is an enormous amount of crappy self-help advice. Most supplements do nothing. However, some substances and practices can dramatically improve your life. It's worth being explicit about what those are in my experience. The American medical system endorses all of these treatments and methods, and you can implement them with a doctor's supervision. The only way I differ from the American medical system is that they operate under a paradigm of treating diseases or perhaps what might be better understood as serious deficiencies. But if a technique is powerful enough to help the ill it is plausible it can also help the well. Make your own choices and set yourself free. Before reading this advice, it is important to note that drug users use a lot of drugs. In general, recreational drug users take their drugs at doses so much higher than psychiatric patients that they're basically two different chemicals. A lot of our impressions of drugs, what side effects they have, and how dangerous they are get shaped by the recreational users, not the patients. This is sometimes even true for the doctors who are supposed to prescribe to the patients and give them good advice. While studies of recreational user populations can sometimes be helpful in flagging an issue for consideration, we should be judging the clinical risks based on studies of clinical populations. Ketamine Ketamine is extremely effective and extremely fast-acting. It often solves depression in a single day. Hence, it should be among the first things you try if you have mood issues. From Scott's writeup: The short version: Ketamine is a new and exciting depression treatment, which probably works by activating AMPA receptors and strengthening synaptic connections. It takes effect within hours and works about two or three times as well as traditional antidepressants. Most people get it through heavily regulated and expensive esketamine prescriptions or even more expensive IV ketamine clinics. Still, evidence suggests that getting it prescribed cheaply and conveniently from a compounding pharmacy is equally effective. A single dose of ketamine lasts between a few days and a few weeks, after which some people will find their depression comes back; long-term repeated dosing with ketamine anecdotally seems to work great but hasn't been formally tested for safety. 6: How effective is ketamine? Pretty effective. Studies find the effect of ketamine peaks about 24 hours after use. A meta-analysis finds that by that time, around 50% of patients are feeling better (defined as 50% symptom reduction) compared to less than 10% of patients who got a placebo. A more recent Taiwanese study finds roughly similar numbers. Another way to measure effectiveness is through effect size statistics. The effect size of normal antidepressants like SSRIs is around 0.3. The effect size of ketamine is between 0.6 and 1.0, so about two to three times larger. Ketamine is a psychoactive drug. The state it induces is hard to describe, but it can be psychedelic in its own way. My advice is to take enough ketamine that you are clearly quite high but not so much you are 'out in space.' Ideally, the experience won't be very scary. Ketamine is very short-acting. The peak high should only last about 45 minutes, and the total trip should be under two hours. I recommend either doing a very simple breathing meditation (described in detail later in this document) or enjoying media you find uncomplicatedly pleasant. Watch a nature documentary about trees. Don't watch one about predators. Listen to music that makes you happy. It's important to get your setting right. Moving around on ketamine makes people nauseous. So, have water and nausea meds (ondansetron or Dramamine) rig...

Episodio 1271 en colaboración con el podcast El Sonajero de Fisher-Price.Hoy hablamos sobre la importancia del movimiento asociativas de madres y padres en los AMPAS/ AFAS con Mª del Carmen Morillas, presidenta de Federación Regional de Asociaciones de Padres y Madres del Alumnado Francisco Giner de los Ríos.Toda la info sobre la FAPA -> https://www.fapaginerdelosrios.org/Canal de Telegram de Madresfera https://t.me/NoticiasMadresferaWeb: https://madresfera.com/Newsletter semanal: https://www.madresfera.com/newsletter/

Proč Česko odmítlo vyslat zástupce na zasedání Rady bezpečnosti svolané Ruskem? Jak vznikla tradice silvestrovského setkávání Čechů a Slováků na Velké Javořině v Bílých Karpatech? Jak bezpečně otevírat šampaňské a co nesmí chybět na pravém českém obloženém chlebíčku?